je.st
news
Tag: merck
Merck Recalling Combination Cholesterol Drug
2014-01-14 22:07:41| Biotech - Topix.net
Drugmaker Merck & Co. is recalling a combination cholesterol drug, wiping out the entire U.S. stock, due to packaging defects that could reduce effectiveness.
Tags: combination
drug
cholesterol
merck
Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference
2014-01-13 14:35:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Initiates rolling submission of U.S. Biologics License Application (BLA) for MK-3475, the companys anti-PD-1 immunotherapy; expects to complete application in first half of 2014. Prepares for 2014 regulatory actions for V503, vintafolide (EU), vorapaxar, NOXAFIL IV, vaniprevir (Japan) and AIT-Grass and AIT-Ragweed; anticipates filing odanacatib, suvorexant. Evaluates the role of Mercks Animal Health and Consumer Care businesses in the companys strategy for long-term value creation; expects conclusions to be reached and action, if any, to be taken in 2014. Divests assets, including a portion of the U.S. ophthalmics business, SAPHRIS U.S. marketing rights and Sirna Therapeutics, Inc. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today will report on the strategic and operating actions it is taking to drive short- and long-term growth, including sharpening its focus in core markets and therapeutic areas, advancing its innovative pipeline and unlocking the value in non-core areas of its business. Language: English Contact: MerckMedia:Kelley Dougherty, 908-423-4291Steven Cragle, 908-423-3461Investor:Carol Ferguson, 908-500-1101Justin Holko, 908-423- 5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: update
growth
annual
conference
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
2014-01-13 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Expects to Complete Application in First Half of 2014 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, said today it has started a rolling submission to the U.S. Food and Drug Administration (FDA) of a Biologics License Application for MK-3475, the companys investigational anti-PD-1 immunotherapy, for patients with advanced melanoma who have been previously treated with ipilimumab. A rolling submission allows completed portions of the application to be submitted and reviewed by the FDA on an ongoing basis. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046Claire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-500-1101Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
application
license
Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck
2014-01-13 07:51:19| Biotech - Topix.net
Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today the acquisition of Merck's wholly owned subsidiary Sirna Therapeutics, Inc. , comprising intellectual property and RNAi assets including pre-clinical therapeutic candidates, chemistry, siRNA-conjugate and other delivery technologies.
Tags: assets
therapeutic
acquires
merck
Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference
2014-01-10 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck's chairman and chief executive officer, is scheduled to present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 13 at 4:00 p.m. PST (7:00 p.m. EST). Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at http://www.merck.com/investors/events-and-presentations/home.html. Language: English Contact: MerckMedia Contact:Kelley Dougherty, 908-423-4291orInvestor Contact:Carol Ferguson, 908-423-4465 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: present
annual
conference
morgan
Sites : [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] next »